Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 3.1% – Should You Buy?

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose 3.1% during trading on Monday . The company traded as high as $1.77 and last traded at $1.68. Approximately 449,700 shares traded hands during trading, an increase of 52% from the average daily volume of 296,297 shares. The stock had previously closed at $1.63.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Tiziana Life Sciences has an average rating of “Sell”.

Tiziana Life Sciences Stock Performance

The company’s 50 day simple moving average is $1.61 and its two-hundred day simple moving average is $1.80.

Institutional Trading of Tiziana Life Sciences

Large investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new stake in shares of Tiziana Life Sciences in the first quarter valued at $25,000. Bison Wealth LLC bought a new stake in Tiziana Life Sciences during the 4th quarter worth about $30,000. Marshall Wace LLP acquired a new stake in Tiziana Life Sciences in the 2nd quarter valued at about $39,000. ARS Investment Partners LLC acquired a new stake in Tiziana Life Sciences in the 3rd quarter valued at about $66,000. Finally, Jane Street Group LLC raised its stake in shares of Tiziana Life Sciences by 968.2% in the first quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock worth $181,000 after acquiring an additional 151,858 shares during the last quarter.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.